Fig. 4From: Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalenceOne-way price sensitivity analysis: (a) base case analysis, (b) scenario analysis. BC, base case; GDP, gross domestic product; HIV, human immunodeficiency virus; HIV+, HIV-positive; ICER, incremental cost-effectiveness ratio; ZAR, South African RandBack to article page